COTI-2|cas:1039455-84-9|西域试剂

COTI-2,99.03%

产品编号：Bellancom-19896| CAS NO：1039455-84-9| 分子式：C₁₉H₂₂N₆S| 分子量：366.48

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19896	￥750.00	杭州北京（现货）
Bellancom-19896	￥1250.00	杭州北京（现货）
Bellancom-19896	￥2350.00	杭州北京（现货）
Bellancom-19896	￥3500.00	杭州北京（现货）
Bellancom-19896	￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

COTI-2

产品介绍

COTI-2，一种具有口服活性的，低毒的抗癌活性分子，是一种第三代 p53 突变体 (p53 mutant) 的激活剂。COTI-2 通过激活突变型 p53 和抑制 PI3K/AKT/mTOR 途径发挥作用。COTI-2 诱导多种人肿瘤细胞凋亡 (apoptosis)。COTI-2 通过 p53 依赖和非依赖机制在 HNSCC 中具有抗肿瘤活性。COTI-2 将突变型 p53 转化为野生型构象。

生物活性

COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation.

体外研究

COTI-2 efficiently inhibits the proliferation rate of all the tested cell lines following 72 h of treatment. COTI-2 is significantly effective at inhibiting tumor cell proliferation in all three cell lines (COLO-205, HCT-15, and SW620). Relatively low concentrations of COTI-2 are active against all human glioblastoma cell lines tested (U87-MG, SNB-19, SF-268, and SF-295). COTI-2 treatment of SHP-77 cells with approximate IC₅₀ concentrations results in the induction of early apoptosis among 40 to 47% of total cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

COTI-2 significantly inhibits tumor growth in the HT-29 human colorectal tumor xenografts at a dose of 10 mg/kg. In addition to reducing tumor volumes at specific times post-treatment, COTI-2 also delays the time required for tumors to reach specified volumes. COTI-2 also significantly inhibits tumor growth in the SHP-77 SCLC xenograft model at a dose as low as 3 mg/kg. COTI-2 treatment both reduces U87-MG tumor volumes at specific times post-treatment and lengthens the time required for U87-MG xenografts to grow in nude mice. Control tumors in mice treated with vehicle alone take only 5 days to reach an average volume of 828 mm³ while tumors in animals treated with COTI-2 take double that time (10 days) to reach a similar mean volume (857 mm³). COTI-2 treatment effectively inhibits OVCAR-3 xenograft growth regardless of the route of administration.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 5 mg/mL (13.64 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.7287 mL	13.6433 mL	27.2866 mL
5 mM	0.5457 mL	2.7287 mL	5.4573 mL
10 mM	0.2729 mL	1.3643 mL	2.7287 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 0.67 mg/mL (1.83 mM); Clear solution

此方案可获得 ≥ 0.67 mg/mL (1.83 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 6.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。